Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap
- Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023
- The company’s research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of neurodegenerative diseases
- Annovis continues to expand its position in an ongoing fight against neurodegenerative diseases
Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions, is continuing to make significant strides in the field of neurodegenerative diseases with its latest patent filings. The recent announcement is the filing of a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.
“The invention of a new solid form of our drug, buntanetap, and the subsequent patent filing represent groundbreaking milestones for our company,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis (https://nnw.fm/Vbpia ). “This achievement will allow us not only to continue advancing our pipeline, but also to enhance the drug’s properties, ultimately providing greater benefits to our patients.”
Annovis is dedicated to developing unique treatments that can improve the lives of individuals suffering from neurodegenerative conditions. The company’s research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of these diseases. By addressing the root causes, Annovis aims to slow or even halt disease progression, offering hope to millions of patients worldwide.
Annovis Bio’s pipeline includes several promising candidates, with buntanetap being at the front of the line. The company’s research has shown that buntanetap can penetrate the blood-brain barrier effectively, allowing it to target the central nervous system directly. This capability is crucial for treating diseases like Alzheimer’s and Parkinson’s, where the brain is the primary site of pathology.
Michael Christie, Ph.D., Vice President of Process Chemistry for Annovis, said that as the company continues to advance its pipeline, securing manufacturing rights for new forms of buntanetap is vital. “This ensures we maintain control over the production process, protect our intellectual property, and continue our mission to deliver novel therapeutics for patients suffering from neurodegenerative disorders,” Christie added (https://nnw.fm/wIyEO ).
In addition to buntanetap, Annovis is also exploring other therapeutic avenues, including the development of biomarkers for early diagnosis and disease monitoring. These efforts are aimed at providing a holistic approach to disease management, encompassing early detection, effective treatment, and ongoing monitoring.
Annovis’ mission extends beyond research and development; the company is also deeply committed to patient care. By collaborating with leading academic institutions and healthcare providers, Annovis ensures that its treatments are not only scientifically sound but also aligned with the needs of patients and clinicians.
The company has established numerous partnerships to facilitate clinical trials and gather real-world evidence on the efficacy of its treatments. These collaborations are critical for bringing new therapies to market and ensuring that they can make a tangible difference in patients’ lives.
The company’s creative approach to drug development and delivery sets it apart in the biotechnology industry. With its recent patent filings and ongoing research initiatives, Annovis holds a growing position in the fight against neurodegenerative diseases, a massive market.
For more information, visit the company’s website at www.AnnovisBio.com, and social channels
LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023
- The company’s research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of neurodegenerative diseases
- Annovis continues to expand its position in an ongoing fight against neurodegenerative diseases
Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions, is continuing to make significant strides in the field of neurodegenerative diseases with its latest patent filings. The recent announcement is the filing of a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.
“The invention of a new solid form of our drug, buntanetap, and the subsequent patent filing represent groundbreaking milestones for our company,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis (https://nnw.fm/Vbpia ). “This achievement will allow us not only to continue advancing our pipeline, but also to enhance the drug’s properties, ultimately providing greater benefits to our patients.”
Annovis is dedicated to developing unique treatments that can improve the lives of individuals suffering from neurodegenerative conditions. The company’s research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of these diseases. By addressing the root causes, Annovis aims to slow or even halt disease progression, offering hope to millions of patients worldwide.
Annovis Bio’s pipeline includes several promising candidates, with buntanetap being at the front of the line. The company’s research has shown that buntanetap can penetrate the blood-brain barrier effectively, allowing it to target the central nervous system directly. This capability is crucial for treating diseases like Alzheimer’s and Parkinson’s, where the brain is the primary site of pathology.
Michael Christie, Ph.D., Vice President of Process Chemistry for Annovis, said that as the company continues to advance its pipeline, securing manufacturing rights for new forms of buntanetap is vital. “This ensures we maintain control over the production process, protect our intellectual property, and continue our mission to deliver novel therapeutics for patients suffering from neurodegenerative disorders,” Christie added (https://nnw.fm/wIyEO ).
In addition to buntanetap, Annovis is also exploring other therapeutic avenues, including the development of biomarkers for early diagnosis and disease monitoring. These efforts are aimed at providing a holistic approach to disease management, encompassing early detection, effective treatment, and ongoing monitoring.
Annovis’ mission extends beyond research and development; the company is also deeply committed to patient care. By collaborating with leading academic institutions and healthcare providers, Annovis ensures that its treatments are not only scientifically sound but also aligned with the needs of patients and clinicians.
The company has established numerous partnerships to facilitate clinical trials and gather real-world evidence on the efficacy of its treatments. These collaborations are critical for bringing new therapies to market and ensuring that they can make a tangible difference in patients’ lives.
The company’s creative approach to drug development and delivery sets it apart in the biotechnology industry. With its recent patent filings and ongoing research initiatives, Annovis holds a growing position in the fight against neurodegenerative diseases, a massive market.
For more information, visit the company’s website at www.AnnovisBio.com, and social channels
LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
